A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Bristol-Myers Squibb
Study ID
NCT05372354
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • CC-92480 — DRUG
    Specified dose on specified days
  • Tazemetostat — DRUG
    Specified dose on specified days
  • BMS-986158 — DRUG
    Specified dose on specified days
  • Trametinib — DRUG
    Specified dose on specified days
  • Dexamethasone — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).

Key Dates

Start date
Oct 18, 2022
Status verified
Aug 2025
Primary completion
Oct 12, 2026
Completion
Oct 12, 2026

Study Design

Enrollment
260 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Part 1 Arm A: Dose Finding
  • Experimental: Part 1 Arm B: Dose Finding
  • Experimental: Part 1 Arm C: Dose Finding
  • Active Comparator: Part 2 Arm D: Dose Expansion
  • Experimental: Part 2 Arm E: Dose Expansion
  • Experimental: Part 2 Arm G: Dose Expansion

Primary Outcome Measure

Number of participants with adverse events (AEs) [ Time Frame: From first participant first visit until 28 days after the last participant discontinues study treatment, up to approximately 4 years ]

Central Contacts

  • BMS Study Connect Contact Center www.BMSStudyConnect.com
    855-907-3286
    [email protected]
  • First line of email MUST contain NCT # and Site #.

Locations (5)

FacilityCityStateZIPSite coordinators
UAB Comprehensive Cancer CenterBirminghamAlabama35249
Luciano Costa, Site 0002
205-934-9695
Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer CenterBaltimoreMaryland21287
Syed Abbas Ali, Site 0015
443-287-7104
Dana-Farber Cancer InstituteBostonMassachusetts02215
Monique Hartley-Brown, Site 0010
857-299-5736
John Theurer Cancer Center at Hackensack UMCHackensackNew Jersey07601
David Siegel, Site 0013
551-996-8704
Memorial Sloan Kettering Cancer CenterNew YorkNew York10021
Saad Usmani, Site 0007

Find similar trials in Birmingham, AL

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
UAB Comprehensive Cancer Center· Birmingham, ALJohns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center· Baltimore, MDDana-Farber Cancer Institute· Boston, MAJohn Theurer Cancer Center at Hackensack UMC· Hackensack, NJMemorial Sloan Kettering Cancer Center· New York, NY

Related Studies